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Background: The recent H1N1 influenza pandemic illustrated the shortcomings of the vaccine manufacturing
process. The A/California/07/2009 H1N1 pandemic influenza vaccine or A(H1N1)pdm09 was available late and in
short supply as a result of delays in production caused by low yields and poor antigen stability. Recombinant
technology offers the opportunity to shorten manufacturing time. A trivalent recombinant hemagglutinin (rHA)
vaccine candidate for seasonal influenza produced using the baculovirus expression vector system (BEVS) was
shown to be as effective and safe as egg-derived trivalent inactivated vaccine (TIV) in human clinical studies. In this
study, we describe the characterization of the A/California/07/2009 rHA protein and compare the H1N1 pandemic
rHA to other seasonal rHA proteins.
Results: Our data show that, like other rHA proteins, purified A/California/07/2009 rHA forms multimeric rosette-like
particles of 20–40 nm that are biologically active and immunogenic in mice as assayed by hemagglutination
inhibition (HAI) antibody titers. However, proteolytic digest analysis revealed that A/California/07/2009 rHA is more
susceptible to proteolytic degradation than rHA proteins derived from other seasonal influenza viruses. We
identified a specific proteolytic site conserved across multiple hemagglutinin (HA) proteins that is likely more
accessible in A/California/07/2009 HA, possibly as a result of differences in its protein structure, and may contribute
to lower antigen stability.
Conclusion: We conclude that, similar to the recombinant seasonal influenza vaccine, recombinant A(H1N1)pdm09
vaccine is likely to perform comparably to licensed A(H1N1)pdm09 vaccines and could offer manufacturing
advantages.
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A novel influenza A virus (H1N1) of swine origin
emerged in Mexico and the United States in March and
early April 2009. The virus quickly spread worldwide
through human-to-human transmission resulting in the
World Health Organization raising the influenza pan-
demic alert to the highest level (phase 6) on June 11,
2009 [1-3]. The outbreak and spread of the first influ-
enza pandemic of the 21st century challenged licensed
vaccine manufacturers to rapidly mobilize and generate
a prophylactic vaccine. Delivery of initial doses of
vaccine to the U.S. public coincided with the second
peak of the pandemic, too late to provide timely protec-
tion and highlighting the need for alternative production
platforms [2,4].
Two types of licensed influenza vaccines are available
in the U.S.: trivalent inactivated vaccine and live attenu-
ated influenza vaccine [5,6], both produced in embryo-
nated chicken eggs. The process of preparing a new
vaccine seed strain suitable for growth in eggs can be
quite lengthy, as it involves re-assortment between the
genes of a high yielding donor virus, such as A/Puerto
Rico/8/34, and the hemagglutinin (HA) and neuraminid-
ase (NA) genes of the new influenza strain [7]. The
candidate seed virus strains are then further selected for
high growth capability in eggs before they can be used
for the production of vaccines. This manufacturing
process is not only lengthy but also limited in scalability
due to its dependence on the availability of embryonated
chicken eggs.
The production of purified recombinant hemagglutinin
(rHA) subunit vaccines via the baculovirus expression
vector system (BEVS) is a leading alternative platform for
influenza vaccine manufacture. The most advanced influ-
enza vaccine candidate produced using this technology
(under the trade name FlublokW) is a trivalent composition
of three rHA proteins corresponding to the full length HA
proteins of the seasonally circulating influenza strains
[8-11]. Clinical trials of Flublok have demonstrated that
the vaccine is well-tolerated, immunogenic (as assessed
by the induction of hemagglutination inhibiting [HAI]
antibodies), and provides protection against drifted
influenza viruses [8-10]. The rHA proteins in Flublok
are produced using genetically modified baculoviruses in
lepidopteran insect cells. The proteins are extracted and
purified from cell pellet using a combination of filtration
and column chromatography methods. Bulk vaccine can
be produced within seven weeks of receipt of the HA
gene sequence [9], making it an attractive platform for
pandemic vaccine manufacturing as demonstrated during
the initial outbreaks of H5N1 [12].
The original influenza seed viruses used for the egg-
based production of the A(H1N1)pdm09 vaccine grew
slowly, produced relatively low quantities of HA antigenand showed poor stability [7,13]. The rHA derived from
A/California/07/2009 also revealed differences compared
to other rHA proteins, as the pandemic rHA protein
was more sensitive to proteolytic degradation and
reacted uniquely in the single radial immunodiffusion
(SRID) potency assay.
The objectives of this study were (1) to study the prop-
erties of the A/California/07/2009 rHA protein and
compare it to other rHA proteins derived from seasonal
influenza strains and (2) to develop an understanding of
the cause of the instability observed with this antigen.
Results
Biochemical and biophysical characterization
The electrophoretic mobility of purified A/California/07/
2009 rHA protein was compared to purified rHA
derived from A/New Caledonia/20/1999, A/Solomon
Islands/03/2006, and A/Brisbane/59/2007 H1N1 sea-
sonal influenza strains using reducing and non-reducing
SDS-PAGE (Figure 1). Purified rHA proteins typically
migrate as monomers and disulfide-linked oligomers
under non-reducing conditions. The primary full-length
HA0 band migrates at approximately 62 kDa, and dimer
and trimer bands are approximately 120 and 180 kDa,
respectively. As shown in Figure 1, the A/California/07/
2009 rHA protein displayed electrophoretic mobility
comparable to that of the seasonal rHA H1 proteins.
The lack of protein bands with molecular weight higher
than that of HA0 under reducing conditions indicates
that the oligomeric forms observed under non-reducing
conditions were disulfide-linked. The A/California/07/
2009 HA0 band migrated slightly faster than the HA0
comparators, possibly because A/California/07/2009 HA
protein has only a single glycosylation site in the globu-
lar head (total five glycosylation sites) in contrast to the
nine sites identified in the HA from A/Brisbane/59/
2007 H1N1 virus [14,15]. In addition, less cleavage of A/
California/07/2009 HA0 into HA1 and HA2 was observed.
A/California/07/2009 rHA protein eluted as a single
peak prior to a thyroglobulin molecular weight standard
(~670 kDa) similar to other rHA proteins when analyzed
by HPLC-SEC (Figure 2), demonstrating that rHA pro-
teins form high molecular weight complexes. No peaks
indicative of rHA monomers, dimers, or trimers were
detected. The retention time of A/California/07/2009
rHA was longer (average of 36.0 minutes) than that of
B/Brisbane/60/2008 rHA (31.4 minutes) or A/Perth/16/
2009 rHA (31.1 minutes). This result indicates that A/
California/07/2009 rHA forms a slightly smaller complex
than A/Perth/16/2009 or B/Brisbane/60/2008 rHA.
Dynamic Light Scattering (DLS) data showed that for
all rHAs evaluated, the measured size corresponded to
multimeric protein particles, with the majority falling
between 20 and 40 nm in diameter (Figure 3). A greater
Figure 1 Reducing and non-reducing SDS-PAGE of H1N1 rHA proteins. For each sample, the respective purified rHA protein was diluted to
a concentration of 100 μg/mL in reducing or non-reducing SDS-PAGE sample buffer, and 1 μg was loaded per lane. The samples were separated
using 4 – 12% gradient Nu-PAGE gels and stained with Coomassie Blue. HA0 represents full-length rHA protein and HA1 and HA2 peptide
fragments of HA0. Molecular weights of proteins are shown in kilodaltons. rHA proteins were produced by Protein Sciences Corporation.
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2009 and B/Brisbane/60/2008 had particle diameters
below 20 nm compared to A/Brisbane/59/2007 and A/
Perth/16/2000 rHA. Despite these minor differences, the
DLS results demonstrate that the A/California/07/2009
rHA protein forms particles with size distribution com-
parable to that of other seasonal rHA proteins.
Electron microscopy images of the purified A/California/
07/2009 (H1), A/Brisbane/59/2007 (H1), A/Perth/16/2009
(H3) and B/Brisbane/60/2008 rHA proteins are shown
in Figure 4. A/California/07/2009 rHA formed multi-
meric rosette-like structures consistent with the other
purified rHA proteins but were less distinct compared
to the H3 rHA protein, which formed clearer rosette-like
structures than either the H1 or B rHA proteins. All of
the rHA rosette-like structures measured approximately
30 – 40 nm in size, consistent with the measurements
determined by HPLC-SEC and DLS.
Purified A/California/07/2009 rHA protein showed
increased sensitivity to trypsin compared to other rHA
proteins. Typically, HA0 is cleaved into HA1 and HA2
subunits when treated with trypsin, and we found that
A/California/07/2009 rHA was digested into HA1 and
HA2 peptides in a similar manner (Figure 5). However,
we also found that A/California/07/2009 HA2 was add-
itionally digested into two prominent peptide fragments
of approximately 18 and 6 kDa (designated HA2a and
HA2b, respectively), suggesting the presence of an
additional trypsin proteolytic site.
In order to better characterize HA2a and HA2b and
identify their cleavage site(s), the protein bands were iso-
lated and subjected to N-terminal (Edman) sequencing.
The amino acid sequencing results from the Edman
analyses are shown in Table 1. The results confirm that
purified A/California/07/2009 rHA is produced in its
mature form (N-terminus sequence for HA0 and HA1)with a conserved trypsin cleavage site at Arginine
position 324 [16]. (Note that amino acid numbering is
based on full length sequence.) However, the HA2 poly-
peptide was found to possess an additional cleavage site
at Lysine position 419 (and potential cleavage sites at
Arginine-420, Lysine-426 and Lysine-427).
Alignment of the amino acid sequences of A/California/
07/2009 with A/New Caledonia/20/99, A/Brisbane/59/
2007 and A/Solomon Islands/03/2006 H1 HA proteins
was generated to determine whether sequences and
secondary structure predictions could explain the trypsin
digest results (Figure 6). The alignment results show that
the three potential additional trypsin cleavage sites (i.e.,
Arginine-420, Lysine-426 and Lysine-427) are conserved
among all four HA proteins; however, Lysine-419 is
unique to A/California/07/2009. Therefore, Lysine–419 is
the most likely primary protease digestion site that gener-
ates HA2a and HA2b. Interestingly, according to ExPASy
proteomics tools, amino acids 377 – 427 are predicted to
form a coiled coil domain (indicated by a green over-line
in Figure 6). A/California/07/2009 has six amino acid
changes in this region, including Lysine-419, compared to
the other HA proteins. These sequence differences could
affect protein conformation and make this region more
accessible to trypsin digestion.
Biological activity
A/California/07/2009 rHA protein was evaluated for
functional activity by determining its hemagglutination
activity using red blood cells (RBCs) and comparing it to
the activities of the 2000–2010 seasonal H1 influenza
strain rHAs, A/New Caledonia/20/99, A/Solomon
Islands/03/2006 and A/Brisbane/59/2007. A prerequisite
for hemagglutination activity is the formation of trimers
and the organization of these trimers into higher order
structures that can crosslink corresponding sialic acid
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Figure 2 HPLC-SEC chromatograms of rHA proteins. Volumes corresponding to 17.5 μg of the indicated rHA proteins were injected onto a
Biosuite 450 size exclusion column as described in Materials and Methods. Retention times for the respective rHA proteins were 36.0 minutes
(A/California); 31.4 minutes (B/Brisbane) and 31.1 minutes (A/Perth).
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demonstrated hemagglutination activity with guinea pig
and turkey RBCs but not chicken RBCs (Table 2). This
was most similar to the hemagglutination activity
observed for A/Solomon Islands/03/2006 rHA with
guinea pig and turkey RBCs.
A/California/07/2009 rHA protein activity was also
analyzed using the SRID assay. This assay measures the
potency of influenza vaccines via quantification of func-
tional HA protein [17]. Four lots of A/California/07/2009
reference antigens corresponding to re-assortants X-181and X-179A obtained from both the Center for Biologics
Evaluation and Research (CBER) and the National
Institute for Biological Standards and Control (NIBSC),
and two lots of the A/California/07/2009 rHA (matching
Genbank accession #ACP41953) were tested against
three different antisera generated against hemagglutinin
from A/California/07/2009 (Figure 7). The antisera were
obtained from NIBSC, CBER and Protein Sciences
Corporation, and were generated using HA from egg, E.
coli and BEVS-insect cell sources, respectively. Both the


















Figure 3 Size determination of rHA complexes by Dynamic Light Scattering. The results show the percentage of rHA protein in the size
increments indicated. The results plotted are means of volume-average diameters in the specified size range obtained from multiple lots
(A/California/07/2009 N = 5; A/Brisbane/59/2007 N = 3; A/Perth/16/2009 N = 4; B/Brisbane/60/2008 N = 4).
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CBER antiserum against the HA1 fragment [18] and the
Protein Sciences antiserum against full length rHA).
All of the antisera produced immunoprecipitin rings
with all reference antigens and the A/California/07/2009
rHA protein (Figure 7), indicating that the rHA protein
was antigenically comparable. However, the NIBSC anti-
serum generated against egg-derived antigen produced
larger, more diffuse rings for the rHA (Figure 7A) that
corresponded to calculated potency values that were 2-
to 5-fold greater than the amount of purified rHA pro-
tein inoculated into sample wells (data not shown). In
contrast to the NIBSC antiserum, more well defined
rings for rHA were achieved using antiserum generated
against recombinant antigens (Figure 7B and 7C). Inter-
estingly, both the reference antigens and two separate
licensed A(H1N1)pdm09 monovalent vaccines (from
Novartis and Sanofi Pasteur) reacted differently with the
three antisera, suggesting a unique interaction of each
antiserum with each hemagglutinin produced from the
A/California/07/2009 pandemic H1N1 virus. These
differences had a significant impact on the calculated
potency of the commercial vaccines (Table 3) and
demonstrate the need to have well-matched reagents for
the pandemic H1 vaccine antigens in manufactured
products.
Finally, trivalent formulations of purified rHA vaccine
corresponding to the 2008–2009 and 2010–2011 sea-
sonal influenza strains, the latter of which contained A/
California/07/2009 rHA, were prepared to compare the
immune responses of the different vaccine components.
A commercial egg-based 2009–2010 vaccine (FluLaval,
GSK, Lot # AFLLA599BA, multi-dose formulation) wasincluded as a control. CD-1 mice were administered two
doses of the respective formulations at 21 day intervals,
and hemagglutination inhibition (HAI) antibody titers
were determined three weeks after each dose. The
immunogenicity results are provided in Table 4.
There was a clear dose dependence of the HAI
response to all vaccine components across the test for-
mulations, and the magnitude of the response increased
from Day 21 to Day 42 after the second immunization.
The immune response generated against A/California/
07/2009 (H1) rHA antigen was equal to or slightly
greater than that of A/Brisbane/59/2007 (H1) rHA anti-
gen and the commercial egg-based A/California/07/2009
(H1) control by Day 42. The immune responses were
also consistent for the H3 and B vaccine antigen compo-
nents. These results demonstrate that rHA antigens,
including A/California/07/2009 rHA, produce a robust
immune response.Discussion
The A(H1N1)pdm09 influenza vaccine was available late
and in short supply as a result of delays in production
caused by low yields, poor antigen stability and absence
of virus stockpile. Recombinant hemagglutinin-based
vaccines are inherently less susceptible to production
challenges and are a leading alternative for influenza
vaccine manufacture. The most advanced recombinant
influenza vaccine candidate is a trivalent formulation of
seasonal rHA proteins that can be produced significantly
faster than traditional egg-based influenza vaccines and
has been shown to be as effective and safe as egg-
derived trivalent inactivated vaccine (TIV) in human
A/California/07/2009 (H1) rHA A/Brisbane/59/2007 (H1) rHA 
A/Perth/16/2009 (H3) rHA B/Brisbane/60/2008 rHA 
Figure 4 Transmission Electron Microscopy images of purified rHA proteins. All images were obtained at nominal 52,000× magnification.
The white scale bar represents 200 nm.
Figure 5 Trypsin digestion of rHA proteins. rHA proteins were digested with 50 μg/mL trypsin for 30 minutes at 2-8°C. Approximately 1 μg of
rHA protein was loaded per lane under reducing conditions. The two additional HA2 peptides (HA2a and HA2b) are indicated with arrows.
Molecular weights of proteins are shown in kilodaltons. Panel A: Coomassie Blue-stained SDS-PAGE gel. Panel B: Western blot of trypsin-digested
H1 A/California/07/2009 rHA protein. rHA protein was visualized using anti-H1N1 A/California/07/2009 serum from NIBSC (lot 09/152; sheep
506/507).
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Table 1 Edman sequencing results for H1 A/California/07/2009 trypsin digested fragments
Band ID Peptide sequence Cleavage position Comments
HA0 DTLxIGYHAL A-17 Mature N-Terminus
HA1 DTLxIGY(H)A A-17 Mature N-Terminus
HA2 GLFGAIAGFI R-324 Conserved Cleavage Site




HA2b GLFGAIAGFI R-324 Conserved Cleavage Site
x - unmodified Cys based on the known sequence of H1 A/California/07/2009 rHA
N-terminal sequenced peptides were aligned with the H1 A/California/07/2009 amino acid sequence. The trypsin cleavage sites were identified based on
sequence information and ExPASy Proteomic Tools (Peptide Cutter Software).
The trypsin cleavage sites are presented as conserved (for recent H1 strains) or additional cleavage sites (R-420, K-426 and K-427) and additional cleavage site K-419 is
shown in bold.
Figure 6 CLUSTAL multiple sequence alignment and secondary structure prediction for H1 A/California/07/2009, H1 A/New Caledonia/
20/99, H1 A/Brisbane/59/2007 and H1 A/Solomon Islands/03/2006. A structure prediction was established using ExPASy Proteomics Tools
(http://sequerome.georgetown.edu/sequerome, secondary structure prediction). The conserved cleavage site at R-324 is shown with an asterisk.
The additional trypsin cleavage region is over-lined in red. The cleavage site K-419 identified from the digested fragments is indicated by a red
arrow. Additional cleavage sites R-420, K-426 and K-427 are indicated by black arrows. The predicted coiled-coil region is indicated by the green
over-line. The transmembrane domain is shown by the blue over-line. Amino acids that are divergent from the H1 rHA consensus sequence are
highlighted in black. H1 A/California/07/2009 amino acid numbering is based on full length sequence.
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Table 2 Hemagglutination activity of purified H1 A/California/07/2009, H1 A/Brisbane/59/2007, H1 A/New Caledonia/
20/99 and H1 A/Solomon Islands/03/2006 rHA
rHA derived from various H1N1
influenza viruses
Guinea pig red blood cells Chicken red blood cells Turkey red blood cells
(HA units/μg protein)
A/California/07/2009 N = 8 160 <20 60
A/Brisbane/59/2007 N = 6 3200 1706 2560
A/New Caledonia/20/99 N = 2 6400 800 960
A/Solomon Islands/03/2006 N = 2 120 100 40
Hemagglutination values were generated with guinea pig, chicken, and turkey RBCs and HA activity was calculated based on protein BCA (Bicinchoninic Acid)
values.
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promise.
This in-depth characterization of A/California/07/2009
rHA showed that it is biochemically, biophysically, and
antigenically comparable to seasonal rHA antigens. A/
California/07/2009 rHA had an electrophoretic mobility
similar to that of seasonal rHA proteins and formed
higher order, multimeric rosette-like particles of
approximately 20–40 nm. This is in contrast to the
findings of Khurana et al. who expressed full length A/
California/07/2009 HA in a bacterial expression system
and found that the purified protein migrated predomin-
antly as a monomer [18]. The reason for this difference
is unknown but could relate to the different expression
platforms. A/California/07/2009 rHA demonstrated sig-
nificant biological activity and elicited a strong immune
response in mice consistent with that generated by
commercial egg-derived A/California/07/2009 vaccine
both in this study and previously [19,20]. Together, these
data support the suitability of A/California/07/2009 rHAA. NIBSC 




 (rHA)  
CBER NIBSC CBER NIBS
Antiserum
X-179AX-181
Figure 7 SRID comparison of recombinant and egg-derived HA prote
antigens are identified by re-assortant (X-181 or X-179A) and source (CBER
provided in the product circulars. Two licensed H1N1 A/California/07/2009
included in this analysis. The A/California/07/2009 rHA lots were diluted to
SRID gel using sheep antiserum obtained from NIBSC generated against eg
experimental sheep antiserum generated against an E. coli-expressed HA1
Sciences Corporation (PSC) experimental rabbit antiserum generated againas a pandemic influenza vaccine alternative. An initial
clinical study has confirmed the safety and immunogenicity
of this rHA [21].
The antigenic stability of the A(H1N1)pdm09 vaccine was
found to be initially poor [13]. Trypsin digestion of purified
A/California/07/2009 rHA uncovered a unique susceptibility
of the protein to proteolytic cleavage not found in the sea-
sonal rHA comparators. N-terminal (Edman) sequencing
revealed that this cleavage occurs in a subdomain of the
HA2 region of the protein that for most HA proteins are
predicted to be structured as a coiled-coil. We postulate that
the six amino acid changes in this domain in A/California/
07/2009 HA may disrupt this structure, leading to decreased
antigenic stability. Further studies are needed to determine
whether the virus re-assortants ultimately used for egg-
based A(H1N1)pdm09 vaccine manufacture possessed mod-
ifications that impacted protein structure in this region, im-
proving antigen stability. Preliminary assessment suggests
that a purified recombinant rHA derived from re-assortant






ins and anti-serum against H1 A/California/07/2009. Reference
or NIBSC), and were diluted to 30 μg/mL based on the concentrations
monovalent vaccines (Novartis [1] and Sanofi Pasteur [2]) were
a target of 30 μg/mL based on total protein measurements. Panel A:
g-derived A/California/07/2009 HA; Panel B: SRID gel using CBER
domain of A/California/07/2009 HA; Panel C: SRID gel using Protein
st BEVS-insect cell derived rHA.








Potency according to SRID (μg/mL)
SRID antiserum source
CBER NIBSC PSC
Commercial Vaccine 1(Novartis) X-181 CBER 30.5 17.9 17.3
NIBSC 36.6 24.4 22.2
X-179A CBER 71.4 41.0 28.4
NIBSC 88.1 54.2 36.8
Commercial Vaccine 2(Sanofi Pasteur) X-181 CBER 15.5 14.6 17.4
NIBSC 19.1 20.3 22.6
X-179A CBER 47.1 33.6 29.3
NIBSC 59.1 41.8 38.8
SRID potency values are listed in μg/mL. Results were calculated using X-181 or X-179A reference antigens obtained from CBER or NIBSC, using SRID gels
prepared with sheep antiserum obtained from NIBSC against egg-derived A/California/07/2009 HA, sheep antiserum obtained from CBER against E. coli-expressed
recombinant HA1 fragment, or rabbit antiserum produced by Protein Sciences Corporation (PSC) against purified A/California/07/2009 rHA.
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not shown).
Finally, the antigenic potency of A/California/07/2009
rHA, as determined by the SRID assay, showed
dramatic heterogeneity (≥ 2-fold) depending on the
assay reagents used. A similar effect was observed for
licensed egg-derived monovalent vaccines. This vari-
ation indicates that preparation of reagents for potency
testing (antisera and reference antigens) with novel
pandemic influenza viruses requires further assessment
to accommodate recombinant manufacturing strategies
available for rapid pandemic response. Moreover, the
development of alternative potency assays that are less
dependent upon specific antigen-antibody interactions
that could be affected by the manufacturing platform is
warranted.Table 4 Immunogenicity of trivalent vaccine formulations
Vaccine test article Formulation ID Dos
(by
A/Brisbane/10/2007 (H3N2) 2008-2009 rHA Formulation 3.0
B/Brisbane/60/2008
A/Brisbane/59/2007 (H1N1) 0.3
A/Perth/16/2009 (H3N2) 2010-2011 rHA Formulation 3.0
B/Brisbane/60/2008
A/California/07/2009 (H1N1) 0.3
A/Victoria/210/2009 (H3N2) 2010-2011 Commercial Split Virion




HAI titers were measured on serum samples collected 21 days after immunizations
vaccine components and the geometric mean titer (GMT) calculated.
*HAI titers generated using matching H1N1 virus strains. †Statistically different (P <Conclusions
These results show that the production of purified recom-
binant hemagglutinin (rHA) subunit vaccines via the baculo-
virus expression system is a leading alternative platform for
influenza vaccine manufacture. The biochemical, biophysical
and immunological characterization of a purified recombin-
ant A/California/07/2009 (H1N1) hemagglutinin has been
compared to different seasonal rHA proteins and egg-
produced A/California reagents. The data show that
purified A/California/07/2009 rHA molecules exist in
high molecular weight complexes and form rosette-like
particles of 20 – 40 nm in size. Biochemically, the pro-
tein exhibits hemagglutination activity and a greater
sensitivity to tryptic digestion with additional cleavage
in the HA2 subunit. The unique structure of this
particular HA antigen may account for poor stability.e
SRID)
H3/Perth GMT H1N1 GMT* B/Brisbane GMT
Day 21 Day 42 Day 21 Day 42 Day 21 Day 42
μg/HA 19.1 63.5 183.8 670.3 38.2 442.2
μg/HA 7.2 9.5 66.5 403.2 13.2 96.2
μg/HA 237.8 2560.0 226.3 1403.9† 29.7 735.2
μg/HA 121.8 1612.7 115.8 670.3 8.7 87.7
μg/HA 477.9 3079.7 211.1 557.1 45.9 403.2
μg/HA 152.7 1280.0 83.8 242.5 14.5 57.9
(Day 21 = one immunization; Day 42 = two immunizations) for the respective
0.01) from A/California commercial vaccine high dose group.
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antigenically similar to egg-derived virus and showed
immunogenicity and development of neutralizing antibody
titers in mice.
Methods
rHA cloning and baculovirus generation
The H1 A/California/07/2009 cDNA was generated by
using influenza viral RNA as a template in a reverse tran-
scriptase PCR reaction (RT-PCR). The cDNA was cloned
into baculovirus transfer vector pPSC12, and positive clones
were confirmed by DNA sequencing to be identical to the
H1 A/California/07/2009 reference sequence (GenBank
accession # ACP41953). Spodoptera frugiperda Sf9 cells
were co-transfected with linearized Autographa californica
multiple capsid nucleopolyhedrovirus (AcMNPV) genomic
DNA and the pPSC12 transfer vector containing H1 A/
California/07/2009 cDNA by calcium phosphate pre-
cipitation. This method generated recombinant baculo-
viruses harboring the gene encoding H1 A/California/
07/2009 by homologous recombination. Recombinant
plaques were isolated and used to generate baculovirus
stocks in expresSF+ W (SF+) insect cells. Further details
on the cloning and expression of other rHAs using this
system are described elsewhere [9,22,23].rHA protein production
The recombinant baculovirus stock was used to produce
the H1 A/California/07/2009 rHA protein. Virus inocu-
lum from the working virus stock was added to 450 L of
SF+ insect cell culture in a 600 L bioreactor at a concen-
tration of 2% (v/v) after the insect cells reached a density
of 2.0 – 2.5 × 106 cells per mL. The infected culture was
incubated at 28°C for 40 – 55 hours and harvested at a
viability of 70 - 80%. A cell pellet was generated by centri-
fugation and the recombinant protein was solubilized
using a buffer containing non-ionic detergent. Cells were
removed by depth filtration, and the clarified extract was
applied to an ion-exchange column. Recombinant HA was
eluted and subsequently bound to a hydrophobic inter-
action column. Following elution, the protein was applied
to a Q-membrane to remove any residual DNA. Finally, Q
filtrate was diafiltered and the rHA protein formulated in
final buffer.
SDS-PAGE and western blot
Proteins were separated using 4-12% NuPAGE Bis-Tris
Gels (Cat# NP0323, Life Technologies Corporation,
Carlsbad, CA) and 1x MES Running Buffer (50 mM
MES, 50 mM Tris, 0.1% sodium dodecyl sulfate, 1 mM
EDTA pH 7.3). Non-reducing SDS-PAGE gel samples
were prepared using 2x non-reducing disruption buffer
(120 mM Tris pH 6.8, 20% glycerol, 4% sodium dodecylsulfate, 0.2% bromophenol blue). Reducing SDS-PAGE
gel samples were prepared using 2x disruption buffer
(120 mM Tris pH 6.8, 20% glycerol, 4% sodium dodecyl
sulfate, 0.2% bromophenol blue, 200 mM dithiothreitol).
The SDS-PAGE gels were fixed in pH 1.1 fixative (25%
methanol, 10% glacial acetic acid, 10% thrichloroacetic
acid) for 10 minutes, followed by staining in Coomassie
Blue staining solution (0.1% Brilliant Blue R, 7.7 M re-
agent alcohol, 1.75 M glacial acetic acid) for 60 minutes.
The gels were de-stained in 10% acetic acid. For the
Western Blot, the separated proteins were transferred to
nitrocellulose membrane (Cat# IB3010, Life Technolo-
gies Corporation) or to polyvinylidenefluoride (PVDF)
membrane (Cat# IB4010, Life Technologies Corporation)
and incubated with a 1:1,000 dilution of A/California/
07/2009 (H1N1) influenza antiserum (Lot #09/152,
sheep 506/507, NIBSC, UK) followed by a 1:3,000 dilution
of anti-sheep IgG (whole molecule) alkaline phosphate
secondary antibody (Cat# A5187, Sigma, St. Louis, MO).
Recombinant H1 A/California/07/2009 proteins were
visualized using chromogenic alkaline phosphatase
substrates, 1x NTB (nitro-blue tetrazolium chloride,
Cat# 0329, Amresco, Solon, OH) and 1x BCIP (5-bromo-
4-chloro-3-indolyl-phosphate, p-toluidine salt, Cat# 0885,
Amresco) in chromagen buffer (2-amino-2-methyl-1-
propanol, Cat# 221, Sigma) per the manufacturers’
instructions.
Trypsin digestion
Reaction mixtures containing an rHA concentration of
250 μg/mL were incubated in the absence or presence of
50 μg/mL trypsin (Cat# T1426, Sigma) for 30 min at
2-8°C. Digestion was stopped by heating the samples in
2x disruption buffer. Samples were analyzed by SDS-
PAGE and Western blotting, as described above.
Hemagglutination assay
The hemagglutination assay was performed in U-bottom 96
well microtiter plates. Recombinant HA antigen (starting
concentration of 1 μg/mL; protein concentration deter-
mined by BCA [Bicinchoninic Acid; Cat# 23225, Thermo
Scientific, Rockford, IL]) was diluted by two-fold serial dilu-
tion to a final dilution of 4,096-fold. Fresh red blood cells
(RBCs) were washed with 1x PBS (pH 7.2) and then added
to the wells. RBCs used include 0.5% chicken RBCs from
Charles River SPAFAS, Charleston, SC (Lot #A101213), 1%
guinea pig RBCs from ViroMed Laboratories, Minnetonka,
MN (Lot#11916), and 0.5% turkey RBCs from ViroMed La-
boratories (lot#10984). After one hour of incubation at room
temperature, the plates were scored for agglutination. The
HA activity is defined by the dilution at which partial agglu-
tination was observed (i.e., 50% of the RBCs were aggluti-
nated or the pellet appeared loose). If only fully agglutinated
and/or tight pellets were observed, the endpoint was
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and tight pellets. If no agglutination was observed in
any well, then the activity of the test article was deemed
less than 20 units/μg of protein.
Size exclusion chromatography (HPLC-SEC)
Size exclusion chromatography (HPLC-SEC) was per-
formed by using an Agilent HPLC System (Agilent
Technologies, Santa Clara, CA) with UV or diode array
detectors and a Biosuite 450, 8 μm HR SEC column
(7.8 × 300 mm) (Waters; Cat#186002166). Samples
were run in a mobile phase containing 1x PBS with
300 mM NaCl pH 7.2 at a flow rate of 0.25 mL/min.
For each monovalent bulk batch of A/California/07/
2009 rHA, 17.5 μg of protein was used. Sizes of rHA
multimers were estimated based on a standard curve gen-
erated using reagents from a gel filtration HMW calibra-
tion kit (Cat# 28-4038-42, GE Healthcare Piscataway, NJ).
Dynamic light scattering
Dynamic Light Scattering was performed on purified
rHA protein using a Malvern Zetasizer Nano-S (Malvern
Instruments, Worcestershire, UK) according to the
manufacturer’s instructions. Zetasizer software (Version
6.20) was used for data analysis. Bulk drug substance
was analyzed without dilution by adding 60–70 μL of
sample to a microcuvette and reading (typically) three sets
of 12–14 individual scans. The volume-average size distri-
butions were averaged and binned to <20 nm, 20–40 nm,
and >40 nm.Electron microscopy
Transmission Electron Microscopy was performed by
Nanoimaging Services (La Jolla, CA). Samples were pre-
pared using a continuous carbon grid method with grids
of nitrocellulose supported 400-mesh copper. Three
microliters of 1:100 diluted samples (~6 μg/mL protein)
were applied to a cleaned grid, blotted with filter paper,
and immediately stained with uranyl formate. Electron
microscopy was performed using an FEI Tecnai T12
electron microscope, operating at 120KeV, equipped
with an FEI Eagle 4 K × 4 K CCD camera using nominal
magnifications of 110,000x (0.10 nm/pixel), 52,000x
(0.21 nm/pixel), and 21,000x (0.50 nm/pixel) at electron
doses of approximately 10–15 e/Å2. Negative stain grids
were transferred into the electron microscope using a
room temperature stage.
Edman sequencing
Approximately 6 μg of trypsin treated or untreated A/
California/07/2009 rHA was loaded on an SDS-PAGE
gel and run under reducing conditions. Protein bands
were transferred to a PVDF membrane and stained with0.1% Coomassie Blue R-250 in 40% methanol and 1%
acetic acid, followed by de-staining with 50% methanol
and water. Protein bands of interest were excised from
the PVDF membrane and submitted to the Protein
Core Facility at Columbia University (New York, NY)
for N-terminal (Edman) sequencing. The stained bands
were sequenced on an Applied Biosystems 494 protein
sequencer according to the manufacturer’s instructions.
Single radial immunodiffusion (SRID) assay
SRID assays were performed as described previously
[17,24]. Briefly, an antibody solution at the optimal
working concentration was mixed with melted 1% agar-
ose (Cat# 50010, SeaKem ME, Lonza, Rockland, ME ) in
1x PBS (pH 7.2) (Cat# 20012–050, Life Technologies
Corporation) at 54° - 56°C. Following solidification on
GelBond film (Cat# 53734, Lonza, Rockland, ME) at
room temperature, 4 mm wells were punched in the
gels. Initial dilutions of test samples and reference
standards were prepared in 1% Zwittergent 3–14 (Cat#
693017, Calbiochem, Darmstadt, Germany), incubated
for 30 min at room temperature, and further diluted
with 1% Zwittergent 3–14 in PBS. Twenty microliter
samples were then applied to the agarose wells. The gels
were placed in a sealed moist chamber at room
temperature for 18 hours. Following incubation, the gels
were washed first with 1x PBS (pH 7.2) and then water,
dried and stained with Coomassie Brilliant Blue R250
(Cat# BO149, Sigma). After de-staining, the gels were
dried, and SRID ring diameters were measured using the
GT Vision SRID Reading Program (GT Vision LLC,
Hagerstown, MD). The diameters of the precipitin rings
were measured in two orthogonal directions. Recombin-
ant HA potency was calculated in μg/mL by the parallel
line bioassay method using reference and test rHA anti-
gen response curves (log antigen dilution vs. log zone
diameter). Statistical parameters for determining test
validity were based on correlation coefficients (r ≥ 0.95)
and the equality of slopes (t < 4.604) between test and
reference antigens. NIBSC antiserum lot 09/152, CBER
experimental antiserum lot H1-Ab-1004 and Protein
Sciences Protein G purified rabbit antiserum were used
in the SRID assay. In addition, X-181 CBER antigen lot
H1-Ag-1002, X-181 NIBSC antigen lot 09/294, X-179A
CBER antigen lot 69, X-179A NIBSC antigen lot 09/174,
and two different purified rHA lots were used. Licensed
(egg-derived) monovalent A/California/07/2009 H1N1
pandemic vaccines from two manufacturers were also
evaluated (Sanofi Pasteur Lot UP088AA and Novartis Lot
110739).
Generation of rabbit polyclonal antibody
New Zealand White Rabbit immunization was performed
under contract with Harlan Bioproducts for Science, Inc.
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col was used. Recombinant H1 A/California/07/2009 was
used as an antigen. Freund’s adjuvant was used to generate
the rabbit antiserum. Approximately 2 mg of antigen at a
minimum protein concentration of 0.5 mg/mL was used per
rabbit. The rabbit antiserum from the final bleed was puri-
fied over a Protein G Sepharose column (Cat# 17-0618-05,
GE Healthcare) per the manufacturer’s recommendations.
The eluted antibody fraction was dialyzed against 1x PBS
(pH 7.2) (Cat# 20012–050, Life Technologies Corporation).
The purified rHA H1 A/California/07/2009 antibody was
used in the SRID assay. All work was conducted ethically,
with animal welfare as a top priority, in full compliance with
national animal welfare regulations, under PHS Assurance
in a fully USDA licensed facility.
[http://www.harlan.com/about_harlan_laboratories/
animal_welfare.hl].
Animal immunization and HA inhibition (HAI) assays
The Animal Core Facility at Colorado State University
(CSU) conducted the immunization and determination of
HAI titers. Briefly, 6 – 8 week old female CD1 mice were
administered trivalent vaccine formulations containing
purified recombinant H1 A/California/07/2009 rHA, H1
A/Brisbane/59/2007 rHA, or an A/California/07/2009
egg-based commercial vaccine in trivalent formulation
(FluLavalW, GSK, Lot # AFLLA599BA, multi-dose
formulation) by intramuscular (IM) injections. The formu-
lated doses were based on SRID.
For HAI titer determination, individual serum samples
were treated with receptor destroying enzyme (RDE, from
Vibrio cholera Denka-Seiken, Tokyo, Japan) to remove non-
specific inhibitors and tested against 4 hemagglutination
units (HAU) of the respective influenza viruses grown in
eggs using 0.5% chicken RBCs as previously described [25].
All serum samples were tested in duplicate at a 1:10 starting
dilution. The HAI titer was defined as the reciprocal of the
greatest dilution that completely inhibited the agglutination
of the chicken RBCs. A titer value of 5 was assigned to
represent responses below the assay detection limit. All
work was performed ethically in compliance with all federal,
state, and local laws, regulations, and policies, as well as
Colorado State University internal policies [http://web.
research.colostate.edu/ACP/Regulations.aspx].
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